 MARLBOROUGH, Mass., Aug. 12, 2021 PRNewswire -- Phio Pharmaceuticals Corp. Nasdaq: PHIO, a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi INTASYLTM therapeutic platform, today reported its financial results for the quarter ended June 30, 2021 and provided a business update. 